

Uri Greenbaum

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6502530/publications.pdf>

Version: 2024-02-01

35
papers

380
citations

933447

10
h-index

839539

18
g-index

38
all docs

38
docs citations

38
times ranked

562
citing authors

#	ARTICLE	IF	CITATIONS
1	Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma. <i>Blood Cancer Discovery</i> , 2022, 3, 385-393.	5.0	29
2	Chimeric antigen receptor T-cell therapy toxicities. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 2414-2424.	2.4	19
3	Prolonged neurotoxicity in a lymphoma patient after CD19-directed CAR T-cell therapy: A case report and brief review of the literature. <i>Advances in Cell and Gene Therapy</i> , 2021, 4, e104.	0.9	1
4	Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome. <i>Leukemia</i> , 2021, 35, 1745-1750.	7.2	15
5	High Levels of Common Cold Coronavirus Antibodies in Convalescent Plasma Are Associated With Improved Survival in COVID-19 Patients. <i>Frontiers in Immunology</i> , 2021, 12, 675679.	4.8	19
6	Patient-Reported Outcomes for Cancer Patients with Hematological Malignancies Undergoing Chimeric Antigen Receptor T Cell Therapy: A Systematic Review. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 390.e1-390.e7.	1.2	15
7	CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity. <i>Blood Advances</i> , 2021, 5, 2799-2806.	5.2	57
8	Outcomes of Second Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Myeloid Leukemia. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 689-695.	1.2	14
9	Refined HLA-DPB1 mismatch with molecular algorithms predicts outcomes in hematopoietic stem cell transplantation. <i>Haematologica</i> , 2021, , .	3.5	6
10	Mismatch in SIRP β , a regulatory protein in innate immunity, is associated with chronic GVHD in hematopoietic stem cell transplantation. <i>Blood Advances</i> , 2021, 5, 3407-3417.	5.2	3
11	Engineered T-cell Receptor T Cells for Cancer Immunotherapy. <i>Cancer Immunology Research</i> , 2021, 9, 1252-1261.	3.4	16
12	Mismatch in Sirp β , a Regulatory Protein in Innate Immunity, Is Associated with Outcomes of Allogeneic Stem Cell Transplantation for Lymphoid Malignancies. <i>Blood</i> , 2021, 138, 1804-1804.	1.4	0
13	Incidence rates and clinical characteristics of primary gastrointestinal non-Hodgkin lymphoma: a population study. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 569-574.	1.6	2
14	Chimeric Antigen Receptor T-Cells in B-Acute Lymphoblastic Leukemia: State of the Art and Future Directions. <i>Frontiers in Oncology</i> , 2020, 10, 1594.	2.8	46
15	AML-317: Outcomes of Second Allogeneic Hematopoietic Cell Transplantation for Patients with Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S202.	0.4	0
16	Kinetics of pre α myelodysplastic syndromes blood values correlate with disease risk and survival. <i>Hematological Oncology</i> , 2020, 38, 782-791.	1.7	1
17	Chimeric Antigen Receptor Therapy: How Are We Driving in Solid Tumors?. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1759-1769.	2.0	9
18	Frontline treatment with the combination obinutuzumab \pm chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group. <i>American Journal of Hematology</i> , 2020, 95, 604-611.	4.1	12

#	ARTICLE	IF	CITATIONS
19	The Easix (Endothelial Activation and Stress Index) Score Predicts for CAR T Related Toxicity in Patients Receiving Axicabtagene Ciloleucef (axi-cel) for Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , 2020, 136, 17-18.	1.4	1
20	Gut Bacterial Diversity Associates with Efficacy of Anti-CD19 CAR T-Cell Therapy in Patients with Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 34-35.	1.4	1
21	Primary peg-filgrastim prophylaxis versus filgrastim given on demand for neutropenia during therapy with cladribine for hairy cell leukemia. <i>Leukemia Research</i> , 2019, 82, 24-28.	0.8	2
22	The prognostic significance of bone marrow involvement in diffuse large B cell lymphoma according to the flow cytometry. <i>Leukemia and Lymphoma</i> , 2019, 60, 2477-2482.	1.3	9
23	Front-Line Treatment with Obinutuzumab ± Chlorambucil for Chronic Lymphocytic Leukemia in Real-World Clinical Practice: Results of a Multinational, Multicenter Study By Eric and Icllsg. <i>Blood</i> , 2019, 134, 1766-1766.	1.4	0
24	Is bone marrow examination always necessary to establish the diagnosis of myelodysplastic syndromes? A proposed non-invasive diagnostic model. <i>Leukemia and Lymphoma</i> , 2018, 59, 2227-2232.	1.3	2
25	Persistently low lymphocyte counts after <scp>FCR</scp> therapy for chronic lymphocytic leukemia are associated with longer overall survival. <i>Hematological Oncology</i> , 2018, 36, 128-135.	1.7	6
26	Hairy Cell Leukemia: Retrospective Analysis of Demographic Data and Outcome of 203 Patients from 12 Medical Centers in Israel. <i>Anticancer Research</i> , 2018, 38, 6423-6429.	1.1	13
27	Outcomes of second-line treatment after fludarabine cyclophosphamide and rituximab in patients with chronic lymphocytic leukemia outside clinical trials. <i>European Journal of Haematology</i> , 2018, 101, 399-406.	2.2	5
28	Can bone marrow cellularity help in predicting prognosis in myelodysplastic syndromes?. <i>European Journal of Haematology</i> , 2018, 101, 502-507.	2.2	6
29	Decreased Iron Overload and Oxidative Stress in Transfusion Dependent Patients with Myelodysplastic Syndromes (MDS) with the Oral Iron Chelator Deferiprone. <i>Blood</i> , 2018, 132, 4381-4381.	1.4	1
30	Diagnosis of Myelodysplastic Syndromes without a Bone Marrow Biopsy: A Non-Invasive Diagnostic Model. <i>Leukemia Research</i> , 2017, 55, S78.	0.8	0
31	Does Bone Marrow Cellularity (BMC) Have a Role in Predicting Prognosis and Survival in Myelodysplastic Syndromes (MDS)?. <i>Leukemia Research</i> , 2017, 55, S142.	0.8	0
32	Extramedullary Hematopoiesis in β^2 -Thalassemia. <i>Mayo Clinic Proceedings</i> , 2015, 90, 1591-1592.	3.0	6
33	Nelfinavir induces adipocyte insulin resistance through the induction of oxidative stress: differential protective effect of antioxidant agents. <i>Antiviral Therapy</i> , 2006, 11, 1051-60.	1.0	21
34	Nelfinavir Induces Adipocyte Insulin Resistance through the Induction of Oxidative Stress: Differential Protective Effect of Antioxidant Agents. <i>Antiviral Therapy</i> , 2006, 11, 1051-1060.	1.0	38
35	SIRP α Mismatch Is Associated With Relapse Protection and Chronic Graft-Versus-Host Disease After Related Hematopoietic Stem Cell Transplantation for Lymphoid Malignancies. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	0